BlackRock Group’s Meridian Bioscience Inc VIVO Stock Holding History

BlackRock Group’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.78M	Buy	100,460 +27,780	+38%	+$488K	﹤0.01%	1846
2016 Q3	$1.4M	Buy	72,680 +2,252	+3%	+$44.1K	﹤0.01%	1858
2016 Q2	$1.37M	Buy	70,428 +1,842	+3%	+$36.1K	﹤0.01%	1788
2016 Q1	$1.41M	Buy	68,586 +3,005	+5%	+$59.2K	﹤0.01%	1737
2015 Q4	$1.35M	Buy	65,581 +589	+0.9%	+$11.3K	﹤0.01%	1711
2015 Q3	$1.11M	Sell	64,992 -1,513	-2%	-$27.7K	﹤0.01%	1813
2015 Q2	$1.24M	Buy	66,505 +9,923	+18%	+$184K	﹤0.01%	1831
2015 Q1	$1.08M	Buy	56,582 +3,569	+7%	+$66K	﹤0.01%	1828
2014 Q4	$872K	Buy	53,013 +5,210	+11%	+$89.4K	﹤0.01%	1965
2014 Q3	$846K	Sell	47,803 -17,670	-27%	-$347K	﹤0.01%	1882
2014 Q2	$1.35M	Sell	65,473 -10,781	-14%	-$222K	﹤0.01%	1659
2014 Q1	$1.66M	Buy	76,254 +1,563	+2%	+$35.8K	﹤0.01%	1708
2013 Q4	$1.98M	Buy	74,691 +4,646	+7%	+$114K	﹤0.01%	1530
2013 Q3	$1.66M	Buy	70,045 +10,866	+18%	+$254K	﹤0.01%	1580
2013 Q2	$1.27M	Buy	+59,179	New	+$1.28M	﹤0.01%	1570

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

BlackRock Group's VIVO Position: Q4 2016 in Review

BlackRock Group increased its Meridian Bioscience Inc (VIVO) stake by 38% in Q4 2016, buying an estimated $488K and bringing the position to 100,460 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

BlackRock Group first reported a position in VIVO in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.98M in Q4 2013. 180 funds tracked by Wall St. Rank hold VIVO as of Q4 2016.

BlackRock Group held 100,460 shares of Meridian Bioscience Inc worth $1.78M as of Q4 2016.
BlackRock Group bought 27,780 Meridian Bioscience Inc shares in Q4 2016, an estimated $488K.
Meridian Bioscience Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1846 holding.
BlackRock Group first reported a position in Meridian Bioscience Inc in Q2 2013 and has held it in 15 quarters since.
BlackRock Group's Meridian Bioscience Inc position peaked at $1.98M in Q4 2013.
180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.